A detailed history of Wells Fargo & Company transactions in Arvinas, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 82,058 shares of ARVN stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82,058
Previous 76,637 7.07%
Holding current value
$2.28 Million
Previous $3.16 Million 30.95%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $132,597 - $219,008
5,421 Added 7.07%
82,058 $2.18 Million
Q1 2024

May 10, 2024

BUY
$36.38 - $52.31 $635,704 - $914,064
17,474 Added 29.54%
76,637 $3.16 Million
Q4 2023

Feb 09, 2024

SELL
$14.19 - $42.33 $25,981 - $77,506
-1,831 Reduced 3.0%
59,163 $2.44 Million
Q3 2023

Nov 13, 2023

SELL
$19.64 - $28.21 $328,734 - $472,178
-16,738 Reduced 21.53%
60,994 $1.2 Million
Q2 2023

Aug 15, 2023

BUY
$21.73 - $31.43 $213,975 - $309,491
9,847 Added 14.51%
77,732 $1.93 Million
Q1 2023

May 12, 2023

BUY
$26.15 - $37.26 $61,452 - $87,561
2,350 Added 3.59%
67,885 $1.85 Million
Q4 2022

Feb 13, 2023

BUY
$32.47 - $57.24 $147,641 - $260,270
4,547 Added 7.46%
65,535 $2.24 Million
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $110,243 - $152,687
2,633 Added 4.51%
60,988 $2.71 Million
Q2 2022

Aug 12, 2022

SELL
$36.01 - $74.24 $981,668 - $2.02 Million
-27,261 Reduced 31.84%
58,355 $2.46 Million
Q1 2022

May 16, 2022

SELL
$60.27 - $81.57 $505,906 - $684,698
-8,394 Reduced 8.93%
85,616 $5.76 Million
Q4 2021

Feb 14, 2022

BUY
$65.85 - $96.21 $865,137 - $1.26 Million
13,138 Added 16.25%
94,010 $7.72 Million
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $1.59 Million - $2.34 Million
21,667 Added 36.6%
80,872 $6.65 Million
Q2 2021

Aug 16, 2021

BUY
$60.45 - $84.26 $30,225 - $42,130
500 Added 0.85%
59,205 $4.56 Million
Q1 2021

May 13, 2021

SELL
$58.19 - $91.37 $1.75 Million - $2.75 Million
-30,111 Reduced 33.9%
58,705 $3.88 Million
Q4 2020

Feb 09, 2021

SELL
$20.19 - $84.93 $82,597 - $347,448
-4,091 Reduced 4.4%
88,816 $7.54 Million
Q3 2020

Nov 05, 2020

BUY
$22.99 - $36.34 $43,359 - $68,537
1,886 Added 2.07%
92,907 $2.19 Million
Q2 2020

Aug 13, 2020

BUY
$29.88 - $56.74 $633,037 - $1.2 Million
21,186 Added 30.34%
91,021 $3.05 Million
Q1 2020

May 14, 2020

BUY
$33.0 - $54.5 $2.3 Million - $3.81 Million
69,835 New
69,835 $2.81 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.48B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.